|Articles|December 1, 2001

New oral agent may improve painful IC symptoms

Shiga, Japan-The improvement of interstitial cystitis symptoms with a still-investigational oral agent correlates well with a reduction in bladder platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) expression, suggesting the agent's potential for treating symptoms in patients with nonulcerative IC.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more